The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021

Sara E. Oliver; Julia W. Gargano; Heather Scobie; Megan Wallace; Stephen C. Hadler; Jessica Leung; Amy E. Blain; Nancy McClung; Doug Campos-Outcalt; Rebecca L. Morgan; Sarah Mbaeyi; Jessica MacNeil; José R. Romero; H. Keipp Talbot; Grace M. Lee; Beth P. Bell; Kathleen Dooling

Journal ArticleOPEN ACCESS

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021

Oliver S
Gargano J
Scobie H
et al.

MMWR. Morbidity and Mortality Weekly Report (2021) 70(9) 329-332

DOI: 10.15585/mmwr.mm7009e4

135Citations

271Readers

Abstract

… 10 public … administration errors, serious adverse events, cases of multisystem inflammatory syndrome, and cases of COVID-19 that result in hospitalization or death after administration …

Cite

CITATION STYLE

APA

Oliver, S. E., Gargano, J. W., Scobie, H., Wallace, M., Hadler, S. C., Leung, J., … Dooling, K. (2021). The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021. MMWR. Morbidity and Mortality Weekly Report, 70(9), 329–332. https://doi.org/10.15585/mmwr.mm7009e4

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021

Abstract

Cite

Register to see more suggestions